Hepatica

Hepatica, developed by Perspectum, is a clinical and surgical decision support tool designed to improve the accuracy of liver health and volume assessment for patients with liver cancer. By combining AI-driven analysis with MRI-based imaging, Hepatica supports pre-surgical planning by providing clinicians with quantitative, clinically validated metrics — all without exposing patients to radiation risk.

The platform consolidates liver health assessment and visualization into a single, comprehensive report, making it suitable for hepatobiliary surgical teams, radiologists, and oncologists involved in the management of liver cancer, including colorectal liver metastases (CRLM) and other hepatic malignancies.

Key Features and Capabilities

• AI-driven liver delineation: Automated, deep-learning-based segmentation of the whole liver and individual Couinaud segments, providing repeatable and reproducible volume measurements.
• Quantitative biomarkers: Built on LiverMultiScan technology, Hepatica quantifies liver fibro-inflammation (cT1) and fat content (PDFF) across the whole liver and for each individual Couinaud segment.
• Future liver remnant (FLR) estimation: Segment-level analysis of volume and health assists clinicians in accurately predicting the future liver remnant to inform resection planning.
• 3D visualization: Provides three-dimensional visualization and quantification of whole liver volume.
• Risk stratification: Supports identification of patients at risk of poor post-operative outcomes, including post-hepatectomy liver failure (PHLF) and prolonged hospital stay following resection surgery.
• Patient-friendly reports: Quantitative assessment of an individual's liver health and volume is presented in one comprehensive, easy-to-interpret report.
• MRI-based, radiation-free: Delivers a safer patient experience by relying entirely on MRI rather than CT-based imaging.

Clinical Evidence and Decision Support

• Clinically validated metrics have been demonstrated to improve the accuracy of pre-operative liver health assessment across multiple published studies.
• A study of two patients with similar pre-operative characteristics undergoing liver resection for CRLM illustrated the tool's utility: one patient with high cT1 and PDFF values and a future liver remnant volume of 23% subsequently experienced post-hepatectomy liver failure, while a second patient with normal biomarker values and a 29% FLR had an uneventful recovery — demonstrating how Hepatica data could inform and potentially alter surgical planning.
• Quantitative MRI biomarkers (cT1 and PDFF) have been shown to predict clinical outcomes and correlate with histopathological features of liver disease, including non-alcoholic steatohepatitis (NASH).
• The tool has demonstrated potential to enable cost savings by lowering post-surgical complication rates and reducing associated inpatient hospital stays.

Workflow Integration and Deployment

• Hepatica is delivered as a PACS-integrated, cloud-based service, enabling seamless integration into existing clinical radiology and surgical workflows.
• A curated selection of clinical publications, brochures, clinician guides, pathway summaries, and educational resources are available to support adoption and interpretation of results.
• A dedicated clinician guide — A Guide to Interpreting Liver Tissue Characterization for Clinicians — is available to assist in understanding and applying the quantitative outputs provided by the platform.